[go: up one dir, main page]

NO20030220D0 - Ny form av (R)-N-[5-metyl-8-(4-metylpiperazin-1-yl)-1,2,3,4- tetrahydro-2-naftyl]-4-morfolinobenzamid - Google Patents

Ny form av (R)-N-[5-metyl-8-(4-metylpiperazin-1-yl)-1,2,3,4- tetrahydro-2-naftyl]-4-morfolinobenzamid

Info

Publication number
NO20030220D0
NO20030220D0 NO20030220A NO20030220A NO20030220D0 NO 20030220 D0 NO20030220 D0 NO 20030220D0 NO 20030220 A NO20030220 A NO 20030220A NO 20030220 A NO20030220 A NO 20030220A NO 20030220 D0 NO20030220 D0 NO 20030220D0
Authority
NO
Norway
Prior art keywords
morpholinobenzamide
methylpiperazin
tetrahydro
naphthyl
methyl
Prior art date
Application number
NO20030220A
Other languages
English (en)
Other versions
NO20030220L (no
Inventor
Per-Olov Bergstroem
Martin Hedberg
Mona Lindstroem
Erica Staahle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20030220D0 publication Critical patent/NO20030220D0/no
Publication of NO20030220L publication Critical patent/NO20030220L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NO20030220A 2000-07-20 2003-01-16 Ny form av (R)-N-[5-metyl-8-(4-metylpiperazin-1-yl)-1,2,3,4- tetrahydro-2-naftyl]-4-morfolinobenzamid NO20030220L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002729A SE0002729D0 (sv) 2000-07-20 2000-07-20 Novel compound form
PCT/SE2001/001643 WO2002008212A1 (en) 2000-07-20 2001-07-17 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide

Publications (2)

Publication Number Publication Date
NO20030220D0 true NO20030220D0 (no) 2003-01-16
NO20030220L NO20030220L (no) 2003-03-14

Family

ID=20280557

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030220A NO20030220L (no) 2000-07-20 2003-01-16 Ny form av (R)-N-[5-metyl-8-(4-metylpiperazin-1-yl)-1,2,3,4- tetrahydro-2-naftyl]-4-morfolinobenzamid

Country Status (24)

Country Link
US (1) US6706710B2 (no)
EP (1) EP1305303A1 (no)
JP (1) JP2004504390A (no)
KR (1) KR20030015398A (no)
CN (1) CN1443178A (no)
AR (1) AR029588A1 (no)
AU (2) AU2001272872B2 (no)
BR (1) BR0112619A (no)
CA (1) CA2415046A1 (no)
CZ (1) CZ2003140A3 (no)
EE (1) EE200300028A (no)
HU (1) HUP0301116A3 (no)
IL (1) IL153836A0 (no)
IS (1) IS6679A (no)
MX (1) MXPA03000439A (no)
NO (1) NO20030220L (no)
NZ (1) NZ523528A (no)
PL (1) PL365112A1 (no)
RU (1) RU2002135626A (no)
SE (1) SE0002729D0 (no)
SK (1) SK732003A3 (no)
UA (1) UA72333C2 (no)
WO (1) WO2002008212A1 (no)
ZA (1) ZA200300129B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2307389E (pt) 2008-06-20 2013-03-28 Astrazeneca Ab Derivados de dibenzotiazepina e sua utilização
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
JP6401254B2 (ja) 2013-06-21 2018-10-10 武田薬品工業株式会社 プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9900190D0 (sv) * 1999-01-22 1999-01-22 Astra Ab New compounds
SE9702799D0 (sv) * 1997-07-25 1997-07-25 Astra Ab New compounds

Also Published As

Publication number Publication date
NZ523528A (en) 2004-09-24
SK732003A3 (en) 2003-08-05
CA2415046A1 (en) 2002-01-31
RU2002135626A (ru) 2004-07-27
UA72333C2 (en) 2005-02-15
CN1443178A (zh) 2003-09-17
BR0112619A (pt) 2003-07-29
JP2004504390A (ja) 2004-02-12
HUP0301116A2 (hu) 2003-08-28
MXPA03000439A (es) 2003-06-24
AU7287201A (en) 2002-02-05
US6706710B2 (en) 2004-03-16
NO20030220L (no) 2003-03-14
IL153836A0 (en) 2003-07-31
WO2002008212A1 (en) 2002-01-31
KR20030015398A (ko) 2003-02-20
ZA200300129B (en) 2004-06-25
AU2001272872B2 (en) 2005-08-25
US20030166653A1 (en) 2003-09-04
EE200300028A (et) 2004-10-15
EP1305303A1 (en) 2003-05-02
SE0002729D0 (sv) 2000-07-20
CZ2003140A3 (cs) 2003-06-18
HUP0301116A3 (en) 2006-03-28
IS6679A (is) 2003-01-14
PL365112A1 (en) 2004-12-27
AR029588A1 (es) 2003-07-02

Similar Documents

Publication Publication Date Title
FR20C1039I2 (fr) Derives de l'uk-2a
DE60122196D1 (de) Synergistische antioxidans-kombination von delta tocols und polyphenolen
NO20025450L (no) Ny farmasöytisk sammensetning
DE60030086D1 (de) Interoperabilität von Bluetooth und IEEE 802.11
DE60136181D1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
NO20023616L (no) Ny anvendelse
NO20003640D0 (no) Ny doseringsform
NO995852D0 (no) Ny form av S-omeprazol
NO20034127D0 (no) Forbedring av aromainneholdende bestanddeler
NO20015855D0 (no) Ny anvendelse av forbindelser som antibakterielle midler
DE60132600D1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
NO20030220L (no) Ny form av (R)-N-[5-metyl-8-(4-metylpiperazin-1-yl)-1,2,3,4- tetrahydro-2-naftyl]-4-morfolinobenzamid
DE60126814D1 (de) Inhalation von stickoxid
FR2810231B1 (fr) Cornee synthetique
EE05245B1 (et) N-(1-hdroksmetl-2,3-dihdrokspropl)-1,4,7-triskarboksmetl-1,4,7,10-tetraasatsklododekaani liitiumikompleksid, nende valmistamine ja kasutamine
NO20010654L (no) Ny anvendelse av taxoidderivater
DE60142051D1 (de) Herstellung von perfluorolefinen
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
NO20030868D0 (no) N-(3,5-diklor-2-metoksyfenyl)-4-metoksy-3-piperazin-1-yl- benzensulfonamid
NO20021730L (no) Ny formulering av mirtazapin
MA27240A1 (fr) Derives d'imidazoquinoleine
NO20025964L (no) Ny interferon for behandling av multippel sklerose
DE60007360D1 (de) Amorphe modifikation von torasemid
NO20033163D0 (no) Ny anvendelse av iloperidon

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application